Gibson, Dunn & Crutcher LLP’s life sciences practice represents biotech, pharma, and medical device companies in IP and corporate and commercial transactions. The firm has a strong transactional team advising both issuers and financial institutions in deals across M&A, venture financing, stock and asset acquisitions, and private and public securities offerings. Its patent litigation expertise includes cases under the Hatch-Waxman Act, as well as the enforcement of second- and third-generation, combination drug, and formulation patents. The practice is co-chaired by San Francisco’s Ryan Murr, who is vastly experienced in capital markets transactions, M&A, royalty financing, and corporate governance. Also co-chair, New York-based Jane Love handles high-value patent litigation, patent prosecution, and diligence advice connected to transactions.
Legal 500 redaktioneller Kommentar

Auszeichnungen

Mandantenzufriedenheit

Kernmandanten

  • Merck and Organon
  • Dental Monitoring SAS
  • MedinCell
  • Merck & Co.
  • Royalty Pharma
  • Epygenix Therapeutics, Inc.
  • Apogee Therapeutics, Inc.
  • Ultragenyx Pharmaceutical Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Alcon Inc.

Anwält*innen

Führende Partner*innen

Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.

Praxisleitung

Ryan Murr; Jane Love

Weitere Kernanwält*innen

Branden Berns; Karen Spindler; Chris Trester; Charlotte Jacobsen